Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The objective of this study is to evaluate the efficacy and safety of adalimumab 80 mg loading dose followed by 40 mg dose given every other week subcutaneously starting at Week 1 compared with placebo in subjects with inactive non-infectious intermediate-, posterior-, or pan-uveitis.
Critère d'inclusion
- Inactive non-infectious intermediate-, posterior-, or pan-uveitis